STAAR SURGICAL COSTAAEarnings & Financial Report
STAAR Surgical Co is a global ophthalmic medical device firm. It designs, makes and sells implantable collamer lenses (ICLs) for minimally invasive vision correction, plus supporting surgical products for ophthalmologists across North America, Europe, Asia Pacific and other key regional markets.
Revenue
$76.3M
Gross Profit
$60.7M
Operating Profit
$10.4M
Net Profit
$7.8M
Gross Margin
79.6%
Operating Margin
13.6%
Net Margin
10.2%
YoY Growth
299.4%
EPS
$0.16
STAAR SURGICAL CO Q4 FY2023 Financial Summary
STAAR SURGICAL CO reported revenue of $76.3M (up 299.4% YoY) for Q4 FY2023, with a net profit of $7.8M (up 14.7% YoY) (10.2% margin). Cost of goods sold was $15.5M, operating expenses totaled $50.3M.
Key Financial Metrics
| Total Revenue | $76.3M |
|---|---|
| Net Profit | $7.8M |
| Gross Margin | 79.6% |
| Operating Margin | 13.6% |
| Report Period | Q4 FY2023 |
Revenue Breakdown
STAAR SURGICAL CO Q4 FY2023 revenue of $76.3M breaks down across 3 segments, led by Implantable Collamer Lenses at $46.9M (61.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Implantable Collamer Lenses | $46.9M | 61.5% |
| Other | $23.7M | 31.1% |
| Consignment Sales | $5.6M | 7.4% |
STAAR SURGICAL CO Revenue by Segment — Quarterly Trend
STAAR SURGICAL CO revenue by segment across the last 4 reported quarters, showing how each business line (such as Implantable Collamer Lenses and Other) has evolved quarter over quarter.
| Segment | Q4 FY2024 | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 |
|---|---|---|---|---|
| Implantable Collamer Lenses | — | — | — | $41.5M |
| Other | — | $25.6M | $54.7M | $23.0M |
| Consignment Sales | — | — | $6.8M | $4.7M |
STAAR SURGICAL CO Annual Revenue by Year
STAAR SURGICAL CO annual revenue history includes year-by-year totals (for example, 2024 revenue was $313.9M).
| Year | Annual Revenue |
|---|---|
| 2024 | $313.9M |
| 2023 | $322.4M |
| 2022 | $239.4M |
| 2021 | $124.7M |
STAAR SURGICAL CO Quarterly Revenue & Net Profit History
STAAR SURGICAL CO results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2024 | $49.0M | -35.8% | $-34.2M | -69.9% |
| Q3 FY2024 | $88.6M | +10.3% | $10.0M | 11.3% |
| Q2 FY2024 | $99.0M | +7.3% | $7.4M | 7.5% |
| Q1 FY2024 | $77.4M | +5.2% | $-3.3M | -4.3% |
| Q4 FY2023 | $76.3M | +299.4% | $7.8M | 10.2% |
| Q3 FY2023 | $80.3M | +5.6% | $4.8M | 6.0% |
| Q2 FY2023 | $92.3M | +13.8% | $6.1M | 6.6% |
| Q1 FY2023 | $73.5M | +16.3% | $2.7M | 3.7% |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $73.5M | $92.3M | $80.3M | $76.3M | $77.4M | $99.0M | $88.6M | $49.0M |
| YoY Growth | 16.3% | 13.8% | 5.6% | 299.4% | 5.2% | 7.3% | 10.3% | -35.8% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $418.9M | $440.7M | $471.5M | $488.7M | $492.5M | $512.7M | $537.6M | $509.5M |
| Liabilities | $80.0M | $87.0M | $92.9M | $102.7M | $99.7M | $103.6M | $109.5M | $112.2M |
| Equity | $342.8M | $357.6M | $378.6M | $386.0M | $392.8M | $409.1M | $428.1M | $397.3M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.1M | $-6.3M | $-6.0M | $32.0M | $21.7M | $-10.4M | $3.8M | $642000 |